Citadel Advisors
VRAX icon

Citadel Advisors’s Virax Biolabs VRAX Stock Holding History

Citadel Advisors’s Portfolio VRAX Stock Details VRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,206
Closed -$24.7K – 14237
2025
Q2 		$24.7K Buy
1,206
+664
+123% +$16.2K ﹤0.01% 12057
2025
Q1 		$15.4K Buy
+542
New +$23.9K ﹤0.01% 13316
2024
Q2 		– Sell
-591
Closed -$10.6K – 15510
2024
Q1 		$10.6K Buy
+591
New +$13.8K ﹤0.01% 13452
2023
Q4 		– Sell
-65
Closed -$5.32K – 15334
2023
Q3 		$5.32K Buy
+65
New +$6.09K ﹤0.01% 13408

Other funds holding VRAX

HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Citadel Advisors's VRAX Position: Q3 2025 in Review

Citadel Advisors sold out of Virax Biolabs (VRAX) in Q3 2025, closing a stake of 1,206 shares — an estimated $24.7K sold.

Citadel Advisors first reported a position in VRAX in Q3 2023 and held it in 4 quarters. The position peaked at $24.7K in Q2 2025. 5 funds tracked by Wall St. Rank hold VRAX as of Q3 2025.

  • Citadel Advisors reported no remaining Virax Biolabs position as of Q3 2025 after selling out during the quarter.
  • Citadel Advisors sold 1,206 Virax Biolabs shares in Q3 2025, an estimated $24.7K.
  • Citadel Advisors first reported a position in Virax Biolabs in Q3 2023 and held it in 4 quarters.
  • Citadel Advisors's Virax Biolabs position peaked at $24.7K in Q2 2025.
  • 5 funds tracked by Wall St. Rank held Virax Biolabs as of Q3 2025.

Based on Citadel Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.